BioNTech SE (BNTX)
BioNTech lifts 2025 revenue guidance on BMS partnership payment
Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda.
BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Ryan Richardson - Chief Strategy Officer, MD & Member of Management Board Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Cory William Kasimov - Evercore Inc. Daina Michelle Graybosch - Leerink Partners LLC, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C. Flynn - Morgan Stanley, Research Division Operator Welcome to BioNTech Second Quarter 2025 Earnings Call.
BioNTech's Q2 revenues double on higher COVID vaccine sales
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for July 29th
GDS, U and BNTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 29, 2025.
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis - Berenberg John Newman - Canaccord Genuity Operator Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
